Download PDF
Pneumologie 2016; 70(S 02): S174-S179
DOI: 10.1055/s-0042-120573
Historisches Kaleidoskop
© Georg Thieme Verlag KG Stuttgart · New York

Die zukünftige Geschichte der Lepra

The Forthcoming History of Leprosy
M. Hundeiker
1   Lepramuseum Münster
,
I. D. Bassukas
2   Dermatologische Universitätsklinik Ioannina
› Author Affiliations
Further Information

Publication History

Publication Date:
07 December 2016 (online)

Also available at
    Permissions and Reprints

Einleitung

Jahrzehntelang vor allem im Umfeld der WHO wiederholte Ankündigungen einer baldigen Ausrottung der Lepra waren nie wissenschaftlich vertretbar. Für die „Eradikation“ fehlen die Voraussetzungen. Die Bezeichnung „Elimination“ für bloße Reduktion der Prävalenz unter 1:10 000 ist irreführend. Erreichbar ist nur Kontrolle der Lepra. Entdeckung und Behandlung aller Infizierten ist kaum möglich. Mehr Hoffnung knüpft sich an die Entwicklung von Impfungen. Aber möglicherweise werden sich von selbst genetische Anpassungen durchsetzen, die z. B. in Mitteleuropa schon im Beginn der Neuzeit die Lepra erlöschen ließen.

 

  • Literatur

  • 1 Silva CA, Danelishvili L, McNamara M et al. Interaction of Mycobacterium leprae with human airway epithelial cells: adherence, entry, survival, and identification of potential adhesins by surface proteome analysis. Infect Immun 2013; 81: 2645-2659
    CrossrefPubMedGoogle Scholar
  • 2 Naves MdeM, Ribeiro FA, Patrocinio LG et al. Bacterial load in the nose and its correlation to the immune response in leprosy patients. Lepr Rev 2013; 84: 85-91
    PubMedGoogle Scholar
  • 3 Hundeiker M, Perusquia-Ortiz AM, Bassukas ID. El futuro de la lepra: Ilusiones y realidad. Dermatol Rev Mex 2013; 57: 491-495
    PubMedGoogle Scholar
  • 4 Wennberg-Hilger KK. Das seuchenhafte Auftreten von Lepra in einigen Küstenregionen West-Norwegens im 19. Jahrhundert. Mit einem ergänzenden Bericht über die entsprechende Situation in Schweden. Med. Inaug.-Diss. Bonn: 2011
    PubMedGoogle Scholar
  • 5 Agius-Ferrante A, Depasquale G, Bonnici E et al. The leprosy eradication-project of Malta. Z Tropenmed Parasitol 1973; 24 (Suppl. 01) 49-52
    PubMedGoogle Scholar
  • 6 Briffa DV. 'Eradication' of leprosy from Malta. Lepr Rev 1987; 58: 87-89
    PubMedGoogle Scholar
  • 7 Aranzazu N, Parra JJ, Cardenas M et al. Cojedes: a leprosy hyperendemic state. Int J Dermatol 2012; 51: 186-194
    CrossrefPubMedGoogle Scholar
  • 8 Alencar CH, Ramos AN Jr, Barbosa JC et al. Persisting leprosy transmission despite increased control measures in an endemic cluster in Brazil: the unfinished agenda. Lepr Rev 2012; 83: 344-353
    PubMedGoogle Scholar
  • 9 Bassukas ID, Gaitanis G, Hundeiker M. Leprosy and the natural selection for psoriasis. Medical Hypotheses 2012; 78: 183-196
    CrossrefPubMedGoogle Scholar
  • 10 Singal A, Sonthalia S. Leprosy in post-elimination era in India: difficult journey ahead. Indian J Dermatol 2013; 58: 443-446
    CrossrefPubMedGoogle Scholar
  • 11 Han XY, Seo YH, Sizer KC et al. A new Mycobacterium species causing diffuse lepromatous leprosy. Am J Clin Pathol 2008; 130: 856-864
    CrossrefPubMedGoogle Scholar
  • 12 Gillis TP, Scollard DM, Lockwood DN. What is the evidence that the putative Mycobacterium lepromatosis species causes diffuse lepromatous leprosy?. Lepr Rev 2011; 82: 205-209
    PubMedGoogle Scholar
  • 13 Jessamine PG, Desjardins M, Gillis T et al. Leprosy-like illness in a patient with Mycobacterium lepromatosis from Ontario, Canada. J Drugs Dermatol 2012; 11: 229-233
    PubMedGoogle Scholar
  • 14 Cole ST, Eiglmeier K, Parkhill J et al. Massive gene decay in the leprosy bacillus. Nature 2001; 409: 1007-1011
    CrossrefPubMedGoogle Scholar
  • 15 Monot M, Honoré N, Garnier T et al. On the origin of leprosy. Science 2005; 308: 1040-1042
    CrossrefPubMedGoogle Scholar
  • 16 Monot M, Honoré N, Garnier T et al. Comparative genomic and phylogeographic analysis of Mycobacterium leprae. Nat Genet 2009; 41: 1282-1289
    CrossrefPubMedGoogle Scholar
  • 17 Achtman M. Insights from genomic comparisons of genetically monomorphic bacterial pathogens. Philos Trans R Soc Lond B Biol Sci 2012; 367: 860-867
    CrossrefPubMedGoogle Scholar
  • 18 Meyers WM, Gormus BJ, Walsh GP. Nonhuman sources of leprosy. Int J Lepr Other Mycobact Dis 1992; 60: 477-480
    PubMedGoogle Scholar
  • 19 Walsh GP, Meyers WM, Binford CH. Naturally acquired leprosy in the nine-banded armadillo: a decade of experience 1975-1985. J Leukoc Biol 1986; 40: 645-656
    PubMedGoogle Scholar
  • 20 Truman R. Leprosy in wild armadillos. Lepr Rev 2005; 76: 198-208
    PubMedGoogle Scholar
  • 21 Frota CC, Lima LN, Rocha AdaS et al. Mycobacterium leprae in six-banded (Euphractus sexcinctus) and nine-banded armadillos (Dasypus novemcinctus) in Northeast Brazil. Mem Inst Oswaldo Cruz 2012; 107 (Suppl. 01) 209-213
    CrossrefPubMedGoogle Scholar
  • 22 Clark BM, Murray CK, Horvath LL et al. Case-control study of armadillo contact and Hansen's disease. Am J Trop Med Hyg 2008; 78: 962-967
    PubMedGoogle Scholar
  • 23 Lane JE, Walsh DS, Meyers WM et al. Borderline tuberculoid leprosy in a woman from the state of Georgia with armadillo exposure. J Am Acad Dermatol 2006; 55: 714-716
    CrossrefPubMedGoogle Scholar
  • 24 Dowdle WR. The principles of disease elimination and eradication. Bull World Health Organ 1998; 76 (Suppl. 02) 22-25
    PubMedGoogle Scholar
  • 25 Mayr A. Eradikation und Tilgung von Seuchen. Dtsch Ärztebl 2006; 103 A: 3115-3118
    PubMedGoogle Scholar
  • 26 Hart BE, Tapping RI. Genetic Diversity of Toll-like Receptors and Immunity to M. leprae Infection. J Trop Med DOI: 10.1155/2012/415057.
    PubMedGoogle Scholar
  • 27 Fava V, Orlova M, Cobat A et al. Genetics of leprosy reactions: an overview. Mem Inst Oswaldo Cruz 2012; 107 (Suppl. 01) 132-142
    CrossrefPubMedGoogle Scholar
  • 28 Cardoso CC, Pereira AC, de Sales MarquesC et al. Leprosy susceptibility: genetic variations regulate innate and adaptive immunity, and disease outcome. Future Microbiol 2011; 6: 533-549
    CrossrefPubMedGoogle Scholar
  • 29 Boldt AB, Sanchez MI, Stahlke ER et al. Susceptibility to leprosy is associated with M-ficolin polymorphisms. J Clin Immunol 2013; 33: 210-219
    CrossrefPubMedGoogle Scholar
  • 30 Klatser PR, van Beers S, Madjid B et al. Detection of Mycobacterium leprae nasal carriers in populations for which leprosy is endemic. J Clin Microbiol 1993; 31: 2947-2951
    PubMedGoogle Scholar
  • 31 Naves MdeM, Ribeiro FA, Patrocinio LG et al. Bacterial load in the nose and its correlation to the immune response in leprosy patients. Lepr Rev 2013; 84: 85-91
    PubMedGoogle Scholar
  • 32 Turankar RP, Lavania M, Singh M et al. Dynamics of Mycobacterium leprae transmission in environmental context: Deciphering the role of environment as a potential reservoir. Infect Genet Evol 2012; 12: 121-126
    CrossrefPubMedGoogle Scholar
  • 33 Alter A, Grant A, Abel L et al. Leprosy as a genetic disease. Mamm Genome 2011; 22: 19-31
    CrossrefPubMedGoogle Scholar
  • 34 Fitness J, Tosh K, Hill AVS. Genetics of susceptibility to leprosy. Genes and Immunity 2002; 3: 441-453
    CrossrefPubMedGoogle Scholar
  • 35 Johnson CM, Lyle EA, Omueti KO et al. Cutting edge: A common polymorphism impairs cell surface trafficking and functional responses of TLR1 but protects against leprosy. J Immunol 2007; 178: 7520-7524
    CrossrefPubMedGoogle Scholar
  • 36 Convit J, Gonzales CL, Rassi E. Estudios sobre lepra en el grupo étnico alemán de la Colonia Tovar, Venezuela. Internat J Leprosy 1952; 20: 185-193
    PubMedGoogle Scholar
  • 37 Hohmann N, Voss-Böhme A. The epidemiological consequences of leprosy-tuberculosis co-infection. Math Biosci 2013; 241: 225-237
    CrossrefPubMedGoogle Scholar
  • 38 De Sales Marques C, Brito-de-Souza VN, Guerreiro LT et al. Toll-like Receptor 1 N248S Single-Nucleotide Polymorphism Is associated with leprosy risk and regulates immune activation during mycobacterial infection. J Infect Dis 2013; 208: 120-129
    CrossrefPubMedGoogle Scholar
  • 39 Lydakis C, Ioannidou D, Koumpa I et al. Development of lepromatous leprosy following etanercept treatment for arthritis. Clin Rheumatol 2012; 31: 395-398
    CrossrefPubMedGoogle Scholar
  • 40 De Freitas MR, Said G. Leprous neuropathy. Handb Clin Neurol 2013; 115: 499-514
    PubMedGoogle Scholar
  • 41 Reinar LM, Forsetlund L, Bjrndal A et al. Interventions for skin changes caused by nerve damage in leprosy. Sao Paulo Med J 2013; 131: 210
    CrossrefPubMedGoogle Scholar
  • 42 Rodriguez G, Pinto R, Gomez Y et al. Pure neuritic leprosy in patients from a high endemic region of Colombia. Lepr Rev 2013; 84: 41-50
    PubMedGoogle Scholar
  • 43 Sales AM, Campos DP, Hacker MA et al. Progression of leprosy disability after discharge: is multidrug therapy enough?. Trop Med Int Health 2013; 18: 1145-1153
    CrossrefPubMedGoogle Scholar
  • 44 Scollard DM. The biology of nerve injury in leprosy. Lepr Rev 2008; 79: 242-253
    PubMedGoogle Scholar
  • 45 Scollard DM, Adams LB, Gillis TP et al. The Continuing Challenges of Leprosy. Clin Microbiol Rev 2006; 19: 338-381
    CrossrefPubMedGoogle Scholar
  • 46 Bretan O, De Souza LB, Lastória JC. Laryngeal lesion in leprosy and the risk of aspiration. Lepr Rev 2007; 78: 80-81
    PubMedGoogle Scholar
  • 47 Pallagatti S, Sheikh S, Kaur A et al. Oral cavity and leprosy. Indian Dermatol Online J 2012; 3: 101-104
    CrossrefPubMedGoogle Scholar
  • 48 Sharp D. Leprosy lessons from old bones. Lancet 2007; 369: 808-809
    CrossrefPubMedGoogle Scholar
  • 49 Jacobson RR, Gatt P. Can leprosy be eradicated with chemotherapy? An evaluation of the Malta Leprosy Eradication Project. Lepr Rev 2008; 79: 410-415
    PubMedGoogle Scholar
  • 50 WHO Expert Committee on Leprosy. World Health Organ Tech Rep Ser. 2012. (968) World Health Organization. 1-61 1 p following 61
    PubMedGoogle Scholar
  • 51 Lockwood DN, Suneetha S. Leprosy: too complex a disease for a simple elimination paradigm. Bull World Health Organ 2005; 83: 230-235
    PubMedGoogle Scholar
  • 52 Geluk A. Challenges in immunodiagnostic tests for leprosy. Expert Opin Med Diagn 2013; 7: 265-274
    CrossrefPubMedGoogle Scholar
  • 53 Naafs B. Treatment of Leprosy: science or politics?. Tropical Medicine & International Health 2006; 11: 268-278
    CrossrefPubMedGoogle Scholar
  • 54 Nsagha DS, Bamgboye EA, Assob JC et al. Elimination of leprosy as a public health problem by 2000 AD: an epidemiological perspective. Pan Afr Med J 2011; 9: 4 [Epub 2011 May 17]
    PubMedGoogle Scholar
  • 55 Barreto JG, Guimarães LdeS, Frade MA et al. High rates of undiagnosed leprosy and subclinical infection amongst school children in the Amazon Region. Mem Inst Oswaldo Cruz 2012; 107 (Suppl. 01) 60-67
    CrossrefPubMedGoogle Scholar
  • 56 Beyene D, Aseffa A, Harboe M et al. Nasal carriage of Mycobacterium leprae DNA in healthy individuals in Lega robi village, Ethopia. Epidemiol Infect 2003; 131: 841-848
    CrossrefPubMedGoogle Scholar
  • 57 Silva KKMBK, Gunasekera CN, Fernando J. Clinical and histological activity after short duration multidrug therapy for leprosy. Sri Lanka J Dermatol 2003; 7: 22-23
    PubMedGoogle Scholar
  • 58 Duthie MS, Saunderson P, Reed SG. The potential for vaccination in leprosy elimination: new tools for targeted interventions. Mem Inst Oswaldo Cruz 2012; 107 (Suppl. 01) 190-196
    CrossrefPubMedGoogle Scholar
  • 59 Degang Y, Nakamura K, Akama T et al. Leprosy as a model of immunity. Future Microbiol 2014; 9: 43-54
    CrossrefPubMedGoogle Scholar
  • 60 Pattnaik S. Leprosy elimination: Battle won, but the war remains. Natl Med J India 2013; 26: 57-58
    PubMedGoogle Scholar